Tether CEO Paolo Ardoino Talks About the Launch of Dirham-Pegged Stablecoin and New Tokenization Platform

Welcome to the Tether CEO Interview Series: Insights and Laughs with Paolo Ardoino A Candid Conversation with Paolo Ardoino In a recent interview with “The Big Whale,” Tether CEO Paolo Ardoino shared some exciting updates on the company’s plans for expansion and its approach to regulatory challenges, particularly in Europe. As the interview unfolded, Ardoino…

Read More

Breaking News: Cue Biopharma Plans Exciting Public Offering for 2024!

Cue Biopharma Commences Public Offering: A Breakthrough in Therapeutic Biologics What is Cue Biopharma? Cue Biopharma, Inc. (Nasdaq: CUE) is a cutting-edge clinical-stage biopharmaceutical company based in Boston. With a focus on developing a new class of therapeutic biologics, Cue Biopharma aims to selectively engage and modulate disease-specific T cells. Their innovative approach has garnered…

Read More

Oops, We Need a Rain Check: Hennessy Capital Investment Corp VI Delays Special Meeting of Stockholders to September 30th at 10:00 AM ET!

Welcome to the World of Stockholder Meetings! Postponed Meeting, Same Excitement Hey there fellow stockholders! Have you heard the news about the special meeting of Hennessy Capital Investment Corp. VI being postponed? Yes, you read that right. The meeting that was supposed to happen on September 27, 2024, has been rescheduled to September 30, 2024….

Read More

QIAGEN Gets the Green Light: European IVDR Certification for QIAstat-Dx Syndromic Testing Instruments and Assays!

Exciting News in the World of Diagnostic Testing! The Introduction of a Groundbreaking Product Line Have you heard the news? QIAGEN, a global leader in molecular diagnostics, has recently announced that their product line, which includes the QIAstat-Dx Analyzer, QIAstat-Dx Rise, and panels for the detection of gastrointestinal and respiratory infections, has earned the prestigious…

Read More

Breaking News: NurExone Biologic Secures $2M in Private Placement and Completes First Tranche for $1.61M

The Future of Medicine: NurExone Biologic Inc. Announces Private Placement Offering TORONTO and HAIFA, Israel, Sept. 26, 2024 NurExone Biologic Inc. is making waves in the biopharmaceutical industry with their cutting-edge exosome-based therapies. With the announcement of a non-brokered private placement offering, the company is positioning itself for further growth and innovation. The Offering, totaling…

Read More

Breaking News: Riverview Bancorp Inc. Launches Exciting Stock Repurchase Program!

Riverview Bancorp, Inc. Announces Stock Repurchase Program Riverview Bancorp, Inc. Vancouver, Wash., Sept. 26, 2024 (GLOBE NEWSWIRE) Riverview Bancorp, Inc. (Nasdaq GSM: RVSB) (“Riverview” or the “Company”) headquartered in Vancouver, WA, the holding company parent of Riverview Bank, announced that on September 25, 2024, its Board of Directors adopted a stock repurchase program. Under this…

Read More